Further investigation of the mechanism of Doxorubicin release from P105 micelles using kinetic models

Stevenson-Abouelnasr, Dana; Husseini, Ghaleb A.; Pitt, William G.

doi:10.1016/j.colsurfb.2006.11.006

Cited by 38 publications

(39 citation statements)

References 21 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drug release from Pluronic ® micelles at the tumor tissue can be prompted with the use of external physical stimuli. A unique strategy combining micellar inclusion with locally applied ultrasound was explored by Rapoport and colleagues, who designed drug-loaded polymeric micelles for pulsatile release in tumors [67][68][69][70][71][72][73]. The ultrasounds should be applied when maximum micelle accumulation into the tumor is reached; the waiting period depending on the kinetics of the distribution of the micellar system.…”

Section: Polymeric Micelles For Passive Target-ingmentioning

confidence: 98%

PEO-PPO Block Copolymers for Passive Micellar Targeting and Overcoming Multidrug Resistance in Cancer Therapy

Alvarez‐Lorenzo

Sosnik²,

Concheiro

2011

CDT

120

View full text Add to dashboard Cite

Drug carriers tailored to fit the physicochemical properties of anticancer agents and the therapeutic peculiarities of tumor management are envisioned for improving the effectiveness/toxicity ratio of the current treatments. Polymeric micelles are attracting much attention owing to their unique beneficial features: i) core-shell structure capable to host hydrophobic drugs, raising the apparent solubility in aqueous medium; ii) size adequate for a preferential accumulation (passive targeting) within the tumor, exhibiting enhanced permeability and retention (EPR effect), and iii) unimers that modulate the activity of efflux pumps involved in multidrug resistance (MDR). This review focuses on amphiphilic poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO) block copolymers, namely the linear poloxamers (Pluronic® or Lutrol®) and the X-shaped poloxamines (Tetronic®), as components of polymeric micelles able to play these three roles. Specific facets of poloxamers have been highlighted some years ago, but recently their wide range of possibilities is beginning to be fully elucidated and understood. Poloxamines are new excipients in the cancer arena and the comparison of their performance with that of poloxamers may enable to identify aspects of their architecture relevant for the optimization of micellar carriers. Clinical trials in progress indicate that drug-loaded polymeric micelles are beneficial regarding efficiency, safety, and compliance of the treatment and quality of life of the patients. The fact that some copolymers are already approved for internal use and several chemotherapy agents will be off patent soon may help to bring the clinical use of poloxamer- or poloxamine-based micelles into a reality in the coming years.

show abstract

Section: Polymeric Micelles For Passive Target-ingmentioning

confidence: 98%

PEO-PPO Block Copolymers for Passive Micellar Targeting and Overcoming Multidrug Resistance in Cancer Therapy

Alvarez‐Lorenzo

Sosnik²,

Concheiro

2011

CDT

120

View full text Add to dashboard Cite

show abstract

“…Alternatively, small polymeric carriers can have substantial advantages in extended in vivo stability and controlled release, and can also respond to mechanical and thermal activation [22]. Doxorubicin has been shown to release from Pluronic ® P105 micelles with insonation at 20 kHz [41], where such micelles are expected to be stable in vivo for extended periods.…”

Section: Vehiclesmentioning

confidence: 99%

Driving delivery vehicles with ultrasound

Ferrara

2008

Advanced Drug Delivery Reviews

231

167

View full text Add to dashboard Cite

Therapeutic applications of ultrasound have been considered for over 40 years, with the mild hyperthermia and associated increases in perfusion produced by ultrasound harnessed in many of the earliest treatments. More recently, new mechanisms for ultrasound-based or ultrasound-enhanced therapies have been described, and there is now great momentum and enthusiasm for the clinical translation of these techniques. This dedicated issue of Advanced Drug Delivery Reviews, entitled "Ultrasound for Drug and Gene Delivery," addresses the mechanisms by which ultrasound can enhance local drug and gene delivery and the applications that have been demonstrated at this time. In this commentary, the identified mechanisms, delivery vehicles, applications and current bottlenecks for translation of these techniques are summarized. KeywordsUltrasound; Therapy; Drug delivery; Gene delivery; Sonoporation; Cavitation As an imaging modality, ultrasound is widely employed and valued for its real time applications, low cost, simplicity, and safety. Waves of alternating increased and decreased pressure propagate from the transducer, typically resulting in a maximum intensity in a focal region chosen by the operator. The dimensions of the focal region can vary from tens of microns for high frequency ultrasound to centimeters for an unfocused therapeutic beam. Most clinical instruments are engineered to effectively image from the body surface to 24 or more centimeters in depth. The ability to locally control and maximize energy deposition deep within the body facilitates a broad range of clinical opportunities for ultrasound imaging and therapy. Developing over four decades, clinical and commercial application of ultrasonic therapies spans hyperthermia, drug delivery, lipoplasty, and thrombolysis [1,2]. A complete and precise summary of the potential applications for ultrasonic enhancement of drug and gene delivery remains challenging as the mechanisms are multiple and not fully characterized. From an engineering viewpoint, the methods by which ultrasound facilitates drug and gene delivery can be summarized as direct changes in the biological or physiological properties of tissues facilitating transport, direct changes in the drug or vehicle increasing bioavailability or enhancing efficacy, and indirect effects by which ultrasound acts on the vehicle to produce changes in the surrounding tissue. While there are common mechanisms between these methods, the engineering challenges associated with the optimization of ultrasound systems and drug and vehicle design are unique for each method. Promising examples of each of these methods can be identified at this time and are addressed below.☆ This commentary is part of the Advanced Drug Delivery Reviews theme issue on "Ultrasound in Drug and Gene Delivery".

show abstract

“…Recently, Stevenson-AbuoelNasr et al developed a new kinetic model to account for the triphasic nature of the release profile (67). The new model introduced 5 different constants in an attempt to capture the complex behavior of release, namely the rate of micelle destruction, micelle assembly, drug re-encapsulation, nuclei destruction and the maximum amount of Dox that micelles can hold.…”

Section: Ultrasonic Drug Releasementioning

confidence: 99%

The Use of Ultrasound and Micelles in Cancer Treatment

Husseini

Pitt²

2008

j nanosci nanotechnol

Self Cite

View full text Add to dashboard Cite

The high toxicity of potent chemotherapeutic drugs like Doxorubicin (Dox) limits the therapeutic window in which they can be applied. This window can be expanded by controlling the drug delivery in both space and time such that non-targeted tissues are not adversely affected. Recent research has shown that ultrasound (US) can be used to control the release of Dox and other hydrophobic drugs from polymeric micelles in both time and space. It has also been shown using an in vivo rat tumor model that Dox activity can be enhanced by ultrasound in one region, while in an adjacent region there is little or no effect of the drug. In this article, we review the in vivo and in vitro research being conducted in the area of micellar drug delivery and ultrasound to cancerous tissues. Additionally, we summarize our previously published mathematical models that attempt to represent the release and re-encapsulation phenomena of Dox from Pluronic ® P105 micelles upon the application of ultrasound. The potential benefits of such controlled chemotherapy compels a thorough investigation of role of ultrasound (US) and the mechanisms by which US accomplishes drug release and/or enhances drug potency. Therefore we will summarize our findings related the mechanism involved in acoustically activated micellar drug delivery to tumors.

show abstract

Further investigation of the mechanism of Doxorubicin release from P105 micelles using kinetic models

Cited by 38 publications

References 21 publications

PEO-PPO Block Copolymers for Passive Micellar Targeting and Overcoming Multidrug Resistance in Cancer Therapy

PEO-PPO Block Copolymers for Passive Micellar Targeting and Overcoming Multidrug Resistance in Cancer Therapy

Driving delivery vehicles with ultrasound

The Use of Ultrasound and Micelles in Cancer Treatment

Contact Info

Product

Resources

About